No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 24 of the 39 quarters in the window, leaving 15 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 281.8x · 10Y median 74.5x · 82nd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:03:38.565Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T17:03:38.565Z. Latest historical point 2022-05-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T17:03:38.565Z. Latest historical point 2022-05-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T17:03:38.565Z. Latest historical point 2022-05-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T17:03:38.565Z. Latest historical point 2022-05-10.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T17:03:38.565Z. Latest historical point 2022-05-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:03:38.565Z. Latest historical point 2022-05-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:03:38.565Z. Latest historical point 2022-05-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Ovid Therapeutics Inc. (OVID) stock was $2.39 as of Oct 6, 2026, 1:00 PM EDT, up 2.15% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +27.0% · 3-year avg -13.1%/yr · 5-year avg -7.0%/yr
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States.
Biotechnology · New York City, NY
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.08
Revenue Est.
$38000.00
Last Quarter Results
EPS
$-0.08
vs Estimate
$-0.10
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1OVID | $446.11M | $2.39 | +2.15% | +27.03% | -6.98% | N/A | N/A |
| 2NPCE | $444.52M | $13.04 | -1.38% | +20.95% | -4.94% | N/A | vs OVID |
| 3DMAC | $448.71M | $8.33 | -1.10% | +19.00% | +16.41% | +7.89% | vs OVID |
| 4CAPR | $440.73M | $7.66 | -1.50% | -0.39% | +15.17% | -13.84% | vs OVID |
| 5ASMB | $435.48M | $21.98 | -3.36% | -2.48% | -10.66% | -13.41% | vs OVID |
| 6EDIT | $435.06M | $2.83 | +1.61% | -28.71% | -40.76% | -15.75% | vs OVID |
forward FY estimate
N/A
$733000.00
vs Estimate
$21429.00
Consensus Rating
Based on 9 analysts
Average Price Target
$5.92
+147.5% upside
Low
$4.00
Current
$2.39
High
$9.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.11 | $-0.09 | $-0.05 | 7 |
| Quarter ending Dec 2026 | $-0.11 | $-0.09 | $-0.08 | 7 |
| Quarter ending Mar 2027 | $-0.19 | $-0.09 | $0.01 | 2 |
| Quarter ending Jun 2027 | $-0.19 | $-0.09 | $0.01 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.41 | $-0.37 | $-0.35 | 8 |
| FY 2027 | $-0.55 | $-0.40 | $-0.30 | 8 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $5428.00 | $38000.00 | $70571.00 | 6 |
| Quarter ending Dec 2026 | $19152.00 | $109444.00 | $196999.00 | 6 |
| Quarter ending Mar 2027 | $5833.00 | $33333.00 | $59999.00 | 3 |
| Quarter ending Jun 2027 | $36443.00 | $208250.00 | $374850.00 | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $644701.00 | $812500.00 | $1.40M | 8 |
| FY 2027 | $107770.00 | $319000.00 | $681108.00 | 7 |
